Ishita Drugs (524400)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Pharmaceutical industry provides long-term demand tailwinds
• Trades closer to 52-week low of ₹66 than high of ₹90.85, offering some downside cushion if business stabilizes
• Book value of ₹36.03 provides tangible asset backing despite 2.01 P/B
• ROE of 8.66% and ROCE of 9.91% show some capital efficiency even under stress

Concerns

• Sales declined 23.97% and profit declined 33.33%
• Latest quarter net profit is practically zero on ₹3 crore sales
• Piotroski F-Score of 3/9 signals weak financial health
• No dividend yield and promoter holding undisclosed; P/E of 23.84 is high for a shrinking earnings base

AI Analysis

When I examine Ishita Drugs, I begin with the numbers, because in the end, numbers tell us the truth. This is a ₹22 crore microcap pharmaceutical company, and Mr. Market is asking ₹72.57 per share. What do I get for that? A business whose sales have fallen by 23.97% and whose profits have declined by 33.33%. The latest quarter reported ₹3 crore in sales and net profit of practically zero. That is not the sign of a healthy franchise; it is a sign of stress. Benjamin Graham would remind me to demand a margin of safety. At a P/E of 23.84 and a P/B of 2.01, I am not getting that margin. Book value is ₹36.03, so the stock trades at roughly twice the tangible assets per share. Meanwhile, returns on capital are mediocre—ROE is 8.66% and ROCE is 9.91%. In a business facing this much contraction, I want to see a Piotroski score of at least seven or eight; Ishita scores only 3 out of 9, a clear warning of deteriorating fundamentals. There is no dividend to compensate me while I wait, and promoter holding is undisclosed, leaving me blind on alignment. The debt/equity figure is also unavailable, which adds uncertainty. On the positive side, pharmaceuticals is an industry with durable demand, and the stock trades closer to its 52-week low of ₹66 than its high of ₹90.85. But a good industry does not always make a good investment. The market itself has no conviction. If the business were stabilizing, I might call this a turnaround candidate. Today, with sales shrinking, margins under pressure, and the latest quarter barely break-even, I would classify it as a troubled situation, not yet a value purchase. I will wait for evidence—stabilized quarterly revenue, restored profits, and transparent ownership—before deploying capital. In the meanwhile, this goes to the too-hard pile.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer